MedTrace Logo

A Combination Treatment Reduces Acne Severity and PIHP

NCT05601960 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1785

Last updated 2022-11-01

No results posted yet for this study

Summary

Acne is a chronic, inflammatory skin condition. It may cause scars and post-inflammatory hyperpigmentation (PIHP). PIHP frequently affects individuals with a phototype of IV or above.\[1\] PIHP is worsened by UV radiation, lasts for years and impacts the individual well-being.\[2, 3\] In an observational study, 1785 adults with a phototype ranging from IV to VI with acne and PIHP applied daily for 2 months a dermocosmetic and a tainted sunscreen product (DC, Effaclar® Duo (+); SS, Anthelios® Shaka Fluide SPF 50+, SS; both La Roche-Posay Laboratoire Dermatologique, France.

Conditions

  • Acne
  • Postinflammatory Hyperpigmentation

Interventions

OTHER

anti-acne dermocosmetic

Topical application once daily for 2 months

Sponsors & Collaborators

  • Cosmetique Active International

    lead INDUSTRY

Principal Investigators

  • Rana Shabab · Dermatique Skin Care, Khobar, KSA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05601960 on ClinicalTrials.gov